IP Library Granted Patent US 9,314,424
Granted Patent B2
US 9,314,424 · App. 14/289,448 · Granted Apr 19, 2016

Pastes for injection of a therapeutic agent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,314,424
App. No.
14/289,448
Granted
Apr 19, 2016
Kind
B2
Abstract

Disclosed is a paste for injection of a therapeutic agent, the paste comprising an amount of powder comprising an effective amount of the therapeutic agent, wherein the powder is homogeneously contained within a pharmaceutically acceptable carrier, and wherein the paste comprises an injection volume of 0.1 to 3000 microliters.

Claims (20)

1. A paste for injection of a therapeutic agent, said paste comprising an amount of powder comprising an effective amount of a therapeutic agent selected from a protein, peptide, polypeptide, vaccine, or small molecule, wherein said powder is homogeneously contained within a pharmaceutically acceptable carrier that is a non-solvent to the powder, and wherein said paste comprises an injection volume of 0.1 to 3000 microliters.

2. The paste of claim 1 , wherein said paste is a slurry.

3. The paste of claim 1 , wherein said therapeutic agent is a peptide.

4. The paste of claim 3 , wherein said peptide is glucagon.

5. The paste of claim 1 , wherein said therapeutic agent is a vaccine or small molecule.

6. The paste of claim 1 , wherein said powder is prepared by subjecting the therapeutic agent to lyophilization, spray-drying, freeze-drying, spray-freeze drying or a combination thereof prior to incorporation into said pharmaceutically acceptable carrier.

7. The paste of claim 6 , wherein said powder has a mean particle size ranging from 10 nanometers (0.01 microns) to about 100 microns, with no particles being larger than about 500 microns.

8. The paste of claim 1 , further comprising an effective amount of a stabilizing agent.

9. The paste of claim 8 , wherein said stabilizing agent is a member selected from the group consisting of surfactants, polyoxamers, polyols, gels, amphoteric compounds, and mixtures thereof.

10. The paste of claim 1 , wherein the protein, peptide, polypeptide, vaccine, or small molecule is stable in said paste for at least about 2 months when said paste is stored at room temperature.

11. The paste of claim 1 , wherein said pharmaceutically acceptable carrier is a non-aqueous or semi-aqueous carrier.

12. The paste of claim 11 , wherein said pharmaceutically acceptable carrier is a non-aqueous carrier.

13. The paste of claim 12 , wherein said non-aqueous carrier is a hydrophobic non-aqueous carrier.

14. The paste of claim 12 , wherein said pharmaceutically acceptable carrier is a mixture of at least two non-aqueous carriers.

15. The paste of claim 12 , wherein said pharmaceutically acceptable carrier is selected from the group consisting of alkyl benzoates, aryl benzoates, aralkyl benzoates, triacetin, dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), and mixtures thereof.

16. The paste of claim 1 , comprising an injection volume of 0.3 to 1.2 ml.

17. The paste of claim 1 , comprising an injection volume of 1 μl to 250 μl.

18. The paste of claim 1 , wherein said paste further comprises a pharmaceutically acceptable polymer that imparts thixotropic properties to said paste.

19. The paste of claim 1 , wherein said paste further comprises a pharmaceutically acceptable polymer in an amount effective to slow the release of said therapeutic agent from said paste upon injection.

20. The paste of claim 1 , wherein the protein, peptide, polypeptide, vaccine, or small molecule is incorporated into a liposome or conjugated to or incorporated with a polysaccharide or other another polymer to provide a controlled release of the protein, peptide, polypeptide, vaccine, or small molecule from said paste upon injection.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2024
From: BGEN CORPORATION, KNOWN AS GENERIPHARM INC., A WHOLLY OWNED SUBSIDIARY OF BRESAGEN LIMITED
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 069356/0461 →
REASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Mar 10, 2022
From: OXFORD FINANCE LLC
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 059358/0700 →
SECURITY INTEREST Recorded Mar 9, 2022
From: XERIS PHARMACEUTICALS, INC.; STRONGBRIDGE DUBLIN LIMITED
To: HAYFIN SERVICES LLP
Reel/Frame 059552/0066 →
SECURITY INTEREST Recorded Sep 12, 2019
From: XERIS PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 050362/0445 →